The U.S. Food and Drug Administration now requires all glucagon-like peptide-1 receptor agonist medications to carry a warning for a rare eye condition that can cause permanent vision loss, drugwatch.com reported.
The regulatory update, issued through a drug safety communication, mandates that manufacturers of widely used diabetes and weight-loss drugs update their product labeling. Affected drugs include Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, Victoza, Rybelsus, Soliqua, Xultophy, Foundayo, and generic exenatide.
NAION Causes Sudden Vision Loss Through Reduced Blood Flow
Non-arteritic anterior ischemic optic neuropathy occurs when blood flow drops to the front of the optic nerve. This condition typically causes sudden, painless vision loss in one eye, and the resulting damage is usually permanent.
The FDA reviewed 126 studies encompassing over 134,000 individuals before taking this regulatory action. The data showed that NAION occurred at a rate of roughly 6 cases per 100,000 people each year among those taking GLP-1 medications. In comparison, individuals taking a placebo or alternative diabetes medications experienced about 4 cases per 100,000 people annually.
⚠️ FDA Requires Eye Warning for GLP-1 Drugs The US FDA announced today, 9 November, that manufacturers of all GLP-1 medicines must add a warning to US prescribing information about a potential increased risk of NAION, a rare eye condition that can cause sudden, painless vision…
Real-world insurance data also analyzed by the agency indicated a higher incidence of NAION among GLP-1 users than among patients taking DPP-4 inhibitors. However, researchers found no statistically significant increase in risk when comparing GLP-1 drugs against SGLT-2 inhibitors.
FDA Orders GLP-1 Drugmakers to Add NAION Risks to Labels
- What changed: The FDA ordered all GLP-1 drugmakers to add NAION risks to their product warning labels.
- The symptom: Seek immediate care for sudden, painless vision loss in one eye, especially upon waking, alongside blind spots or blurriness.
- The context: While the risk is statistically low at approximately 6 cases per 100,000 patients yearly, the damage is typically permanent.
The agency initiated its formal evaluation following a July 2024 study published in JAMA Ophthalmology which first connected semaglutide to the optic neuropathy condition. This U.S. action closely mirrors decisions made abroad, as the European Medicines Agency categorized NAION as a very rare side effect for semaglutide products in 2025.
🚨BREAKING: FDA now requires a vision-loss warning on every GLP-1 label, from Ozempic and Wegovy to Mounjaro, Zepbound and Foundayo. The risk is NAION, a rare optic nerve event: 6.4 vs 3.8 cases per 100,000 patient-years across 126 trials.
Whitney Di Bona, an attorney and consumer advocate at Drugwatch, described the decision as an important step for patient autonomy. Patients deserve to know and understand the risks of any medication before deciding to take it, and this label change moves us closer to that standard,
she stated. Anyone starting a GLP-1 from here on out will have information that earlier patients never got.
Patients with Previous NAION Face Higher Ocular Risks
Individuals who have previously suffered from NAION in one eye face a higher risk of developing the condition in the other eye.
For patients with a history of NAION, physicians should evaluate whether the metabolic benefits of continuing a GLP-1 therapy outweigh the ocular risks. The FDA recommends that clinicians promptly refer any patient with suspected NAION to an ophthalmologist and consider discontinuing the medication.
The updated safety requirements may also influence ongoing legal proceedings. Plaintiffs in product liability lawsuits over Ozempic and other GLP-1 medications frequently argue that manufacturers failed to adequately warn patients about optic nerve risks.
Now that the FDA is requiring a warning on the label, patients who start these drugs in the future will have that information, which will likely make claims more difficult for them,
Di Bona noted, adding that past patients may still pursue legal options.
References
- U.S. Food and Drug Administration. Drug Safety Communication: FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Risk.
- JAMA Ophthalmology. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.
- European Medicines Agency. PRAC concludes that eye condition NAION is a very rare side effect of semaglutide medicines.
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
